Sascha Heinitz1,2, Alessio Basolo1, Daniele Piomelli3, Jonathan Krakoff1, Paolo Piaggi1. 1. Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona. 2. Department of Medicine, Division of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany. 3. Department of Pharmacology, University of California Irvine, Irvine, California.
Abstract
Context: Skeletal muscle endocannabinoids and sphingolipids (particularly sphingomyelins) are inversely associated with sleeping energy expenditure (SLEEP) in humans. The endocannabinoid system may increase sphingolipid synthesis via cannabinoid receptor-1. Objective: To investigate in human skeletal muscle whether endocannabinoids are responsible for the effect of sphingomyelins on SLEEP. Design: Muscle endocannabinoid [anandamide (AEA), 2-arachidonoylglycerol (2-AG)], endocannabinoid congeners [oleoylethanolamide (OEA), palmitoylethanolamide (PEA)], and sphingomyelin content were measured with liquid chromatography/mass spectrometry. SLEEP was assessed in a whole-room indirect calorimeter. Mediation analyses tested whether the inverse associations between sphingomyelins and SLEEP depended on endocannabinoids and endocannabinoid-related OEA and PEA. Setting: Inpatient study. Participants: Fifty-three Native Americans who are overweight. Main Outcome Measure: SLEEP. Results: AEA (r = 0.45, P = 0.001), 2-AG (r = 0.47, P = 0.0004), OEA (r = 0.27, P = 0.05), and PEA (r = 0.53, P < 0.0001) concentrations were associated with the total sphingomyelin content. AEA, OEA, and PEA correlated with specific sphingomyelins (SM18:1/23:0, SM18:1/23:1, and SM18:1/26:1) previously reported to be determinants of SLEEP in Native Americans (all r > 0.31, all P < 0.03). Up to half of the negative effect of these specific sphingomyelins on SLEEP was accounted for by AEA (all P < 0.04), rendering the direct effect by sphingomyelins per se on SLEEP negligible (P > 0.05). Conclusions: In skeletal muscle, AEA is responsible for the sphingomyelin effect on SLEEP, indicating that endocannabinoids and sphingomyelins may jointly reduce human whole-body energy metabolism.
Context: Skeletal muscle endocannabinoids and sphingolipids (particularly sphingomyelins) are inversely associated with sleeping energy expenditure (SLEEP) in humans. The endocannabinoid system may increase sphingolipid synthesis via cannabinoid receptor-1. Objective: To investigate in human skeletal muscle whether endocannabinoids are responsible for the effect of sphingomyelins on SLEEP. Design: Muscle endocannabinoid [anandamide (AEA), 2-arachidonoylglycerol (2-AG)], endocannabinoid congeners [oleoylethanolamide (OEA), palmitoylethanolamide (PEA)], and sphingomyelin content were measured with liquid chromatography/mass spectrometry. SLEEP was assessed in a whole-room indirect calorimeter. Mediation analyses tested whether the inverse associations between sphingomyelins and SLEEP depended on endocannabinoids and endocannabinoid-related OEA and PEA. Setting: Inpatient study. Participants: Fifty-three Native Americans who are overweight. Main Outcome Measure: SLEEP. Results:AEA (r = 0.45, P = 0.001), 2-AG (r = 0.47, P = 0.0004), OEA (r = 0.27, P = 0.05), and PEA (r = 0.53, P < 0.0001) concentrations were associated with the total sphingomyelin content. AEA, OEA, and PEA correlated with specific sphingomyelins (SM18:1/23:0, SM18:1/23:1, and SM18:1/26:1) previously reported to be determinants of SLEEP in Native Americans (all r > 0.31, all P < 0.03). Up to half of the negative effect of these specific sphingomyelins on SLEEP was accounted for by AEA (all P < 0.04), rendering the direct effect by sphingomyelins per se on SLEEP negligible (P > 0.05). Conclusions: In skeletal muscle, AEA is responsible for the sphingomyelin effect on SLEEP, indicating that endocannabinoids and sphingomyelins may jointly reduce human whole-body energy metabolism.
Authors: Resat Cinar; Grzegorz Godlewski; Jie Liu; Joseph Tam; Tony Jourdan; Bani Mukhopadhyay; Judith Harvey-White; George Kunos Journal: Hepatology Date: 2013-11-18 Impact factor: 17.425
Authors: Fabio A Iannotti; Cristoforo Silvestri; Enrico Mazzarella; Andrea Martella; Daniela Calvigioni; Fabiana Piscitelli; Paolo Ambrosino; Stefania Petrosino; Gabriella Czifra; Tamás Bíró; Tibor Harkany; Maurizio Taglialatela; Vincenzo Di Marzo Journal: Proc Natl Acad Sci U S A Date: 2014-06-03 Impact factor: 11.205
Authors: S Heinitz; P Piaggi; K L Vinales; A Basolo; J Spranger; D Piomelli; J Krakoff; R Jumpertz von Schwartzenberg Journal: Int J Obes (Lond) Date: 2017-06-13 Impact factor: 5.095
Authors: Eulla Keimili Fernandes Ferreira Cavalheiro; Ana Beatriz Costa; Daniéle Hendler Salla; Mariella Reinol da Silva; Talita Farias Mendes; Larissa Espindola da Silva; Cristini da Rosa Turatti; Rafael Mariano de Bitencourt; Gislaine Tezza Rezin Journal: Cannabis Cannabinoid Res Date: 2021-07-09